Teladoc health president Bliss Kelly sells shares worth $24,331

Bliss Kelly, President of U.S. Group Health at Teladoc Health, Inc. (NYSE:TDOC), recently sold 2,040 shares of the company's common stock. The shares were sold on December 2, 2024, at an average price of $11.927 per share, resulting in a total transaction value of $24,331. The sale comes as Teladoc, currently valued at $1.9 billion, shows strong momentum with positive returns over the past three months despite trading below its InvestingPro Fair Value.

Prior to this sale, Kelly had exercised performance stock units and restricted stock units on November 29, 2024, acquiring a total of 6,081 shares of common stock. These transactions were made at no cost, as the stock units convert on a one-for-one basis. Following these transactions, Kelly now directly owns 32,244 shares of Teladoc Health. According to InvestingPro analysis, Teladoc maintains a "GREAT" overall financial health score despite operating with moderate debt levels. For deeper insights into insider trading patterns and comprehensive financial analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.

In other recent news, Teladoc Health has launched AI enhancements to its Virtual Sitter solution, aiming to improve patient safety and care in hospitals. This technology allows a single staff member to monitor up to 25% more patients, potentially reducing patient falls. The AI-enabled Virtual Sitter is now commercially available and is being rolled out with select clients.

In financial developments, Teladoc Health reported a 3% decrease in consolidated revenue for the third quarter of 2024, settling at $641 million. However, the Integrated Care segment saw a 2.5% rise in revenue, reaching $384 million. On the other hand, the BetterHelp segment experienced a 10% drop in revenue, falling to $257 million.

Goldman Sachs initiated coverage on Teladoc Health, assigning the company's stock a Buy rating. The firm holds a positive outlook for Teladoc's integrated care business, particularly the Chronic Care Segment, which is expected to fuel membership and revenue growth. Furthermore, Goldman Sachs projects a turnaround in Teladoc's BetterHelp strategy, predicting growth following a low point by the end of 2025.

Looking ahead, Teladoc estimates Integrated Care revenue to remain flat or rise up to 2.5% for the fourth quarter, with adjusted EBITDA margins projected between 12.25% and 13.75%. The company's 2025 targets include revenue growth consistent with Q4 2024 trends, focusing on maintaining margins and managing costs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.